PROTEA study: a protocol for a randomised controlled trial evaluating the efficacy, immune effects and cost-effectiveness of oral bacterial lysate therapy to protect moderate–late preterm infants from respiratory tract infections and wheezing
ERJ Open Research, vol. 11, pp. 00591–2024
Abstract
Infants, children and adults born moderate-late preterm (after 30-36 weeks of pregnancy) are at increased risk of respiratory infections, wheezing and lower lung function leading to increased medication use and hospitalisation. Risk factors frequently present in this population are, at least in part, associated with (lack of) exposure to microbes and subsequent perturbations in microbiome and immune system development. This manuscript presents the protocol of the double-blinded randomised placebo-controlled PROTEA trial, which will demonstrate whether treatment with immunomodulatory bacterial lysates (OM-85) can reduce lower respiratory tract infections and wheeze in the first year of life. The follow-up PROTEA-2 trial will identify possible carry-over effects of OM-85 treatment and investigate the clinical effect of continued treatment in the second year of life. Infants included are otherwise healthy infants born after 30-36 weeks of gestation, excluding those small for gestational age (<3rd percentile). They are recruited shortly after birth in 22 medical centres in the Netherlands. Participants will take OM-85 or placebo starting from 6-10 weeks of life till age 1 year (PROTEA study) or 2 years (PROTEA-2 study) and are closely monitored regarding respiratory health through e-applications. Biological samples, lung function measurements and detailed information on covariates will be collected at ages 2, 6, 12 and 24 months. Biological samples will aid in estimating the impact of bacterial lysate administration on immune cell composition, activation and maturation, vaccination responses, and microbiome diversity and maturation. Participant recruitment started in March 2022.
Authors 5
-
Erasmus MC · Sint Franciscus Gasthuis · Erasmus MC - Sophia Children’s Hospital · Franciscus Vlietland
Affiliation as printed
Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
Department of Pediatrics, Division of Respiratory Medicine and Allergology, ErasmusMC-Sophia, University Medical Center Rotterdam, the Netherlands
1Department of Paediatrics, Franciscus Gasthuis & Vlietland
-
Hermelijn H. Smits Aachen
Leiden University · Leiden University Medical Center
Affiliation as printed
Leiden University Center of Infectious Disease, Leiden, The Netherlands
3Leiden University Center of Infectious Disease (LU-CID)
-
Liesbeth Duijts Aachen
Leiden University · Leiden University Medical Center · Erasmus MC · Erasmus MC - Sophia Children’s Hospital
Affiliation as printed
Department of Pediatrics, Division of Respiratory Medicine and Allergology, ErasmusMC-Sophia, University Medical Center Rotterdam, the Netherlands
3Leiden University Center of Infectious Disease (LU-CID)
-
Maastricht University Medical Centre · Maastricht University
Affiliation as printed
Department of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center+, Maastricht, The Netherlands
4Department of Medical Microbiology, Infectious Diseases and Infection Prevention, Maastricht University Medical Center+
-
Erasmus MC · Sint Franciscus Gasthuis · Erasmus MC - Sophia Children’s Hospital · Franciscus Vlietland
Affiliation as printed
Department of Neonatal and Pediatric Intensive Care, Division of Neonatology, ErasmusMC-Sophia, University Medical Center Rotterdam, the Netherlands
Department of Paediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands
1Department of Paediatrics, Franciscus Gasthuis & Vlietland
Cited by 8 stored of 8
8 results
No patents citing this paper on Lens.org (checked 2026-10-11).